- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dr. Vidal on the Lasting Impact of the KATHERINE Trial in HER2-Positive Breast Cancer
Gregory Vidal, MD, PhD, discusses the impact of the phase 3 KATHERINE trial in HER2-positive breast cancer.
- 2x
- 1.75x
- 1.5x
- 1.25x
- 1x, selected
- 0.75x
- 0.5x
- Chapters
- descriptions off, selected
- captions settings, opens captions settings dialog
- captions off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Gregory Vidal, MD, PhD, medical oncologist, the West Cancer Center & Research Institute, discusses the impact of the phase 3 KATHERINE trial (NCT01772472) in HER2-positive breast cancer.
The 2-arm, randomized, open-label study evaluated the safety and efficacy of trastuzumab emtansine (T-DM1; Kadcyla) compared with trastuzumab (Herceptin) in the adjuvant setting for patients with HER2-positive breast cancer.
The KATHERINE trial changed how clinicians approach patients with HER2-positive breast cancer, as T-DM1 achieved activity in the high-risk, HER2-positive subgroup, Vidal says. This provided another treatment option beyond traditional chemotherapy, Vidal explains.
The results of KATHERINE has a bigger effect on the breast cancer landscape than the phase 3 FeDeriCa trial (NCT03493854), Vidal concludes.
Related Content:
